Log In
BCIQ
Print this Print this
 

Xopenex, levalbuterol HCL

  Manage Alerts
Collapse Summary General Information
Company Akorn Inc.
DescriptionLevalbuteroll inhalation solution
Molecular Target Adrenergic receptor beta 2 (ADRB2)
Mechanism of ActionAdrenergic receptor beta 2 (ADRB2) agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationChronic obstructive pulmonary disease (COPD)
Indication DetailsTreat and prevent bronchospasm in pateints with reversible obstructive airway disease.; Treat bronchospasm; Treat bronchospasm in patients with chronic obstructive pulmonary disease (COPD)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$45.0M

$45.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/30/2014

$45.0M

$45.0M

0

Get a free BioCentury trial today